March 29, 2018

Canada’s largest health research platform teams up with University of Toronto to accelerate cancer and chronic disease research

The leaders of the CPTP stand in front of servers storing the Project's data.

Pictured (left to right): Dr. John Mc Laughlin, Executive Director of CPTP; Cindy Morton, Chief Executive Officer of the Canadian Partnership Against Cancer.; and Dr. Philip Awadalla, National Scientific Director of CPTP.

Canadian Partnership for Tomorrow Project (CPTP) enters a new era of scientific activity under the leadership of newly appointed National Scientific Director, Dr. Philip Awadalla

March 29, 2018 (Toronto) – The Canadian Partnership Against Cancer (“the Partnership”) today announced The University of Toronto’s Dalla Lana School of Public Health will be the new national scientific partner of the Canadian Partnership for Tomorrow Project (CPTP) – Canada’s national population cohort for precision health. This new scientific partner will enable a strong national scientific vision for CPTP and support leading-edge research on the possible causes of cancer and chronic diseases, leading to more made-in-Canada discoveries and breakthroughs. In addition, the University has announced that Ontario Institute for Cancer Research (OICR) will be its strategic partner to deliver the expertise and services needed to lead this key research platform.

Continue reading – Canada’s largest health research platform teams up with University of Toronto to accelerate cancer and chronic disease research

March 8, 2018

Collaborating to bring new treatment options to children with brain cancer

Medulloblastoma cells as seen under a microscope

OICR’s Brain Cancer Translational Research Initiative (TRI) and the Terry Fox Precision Oncology for Young People Program (PROFYLE) are partnering to share data and deliver improved treatment options to young brain cancer patients.

Continue reading – Collaborating to bring new treatment options to children with brain cancer

February 9, 2018

Global Alliance for Genomics and Health launches 2018 Strategic Roadmap

The Global Alliance for Genomics and Health (GA4GH) has laid out its plans for the next five years as it continues to align its activities with meeting the key needs of the genomics data community. The Strategic Roadmap encompasses the standards and frameworks that will be developed by GA4GH and will be updated with new deliverables annually. OICR is a GA4GH Host Institution.

Continue reading – Global Alliance for Genomics and Health launches 2018 Strategic Roadmap

December 7, 2017

Finding new ways to prevent virus-induced stomach cancers

An illustration of the Epstein-Barr virus

The link between some viruses and cancer has long been established. Now, researchers like OICR’s Dr. Ivan Borozan are using genomic sequencing to analyze common viruses like Epstein-Barr (also called human herpes virus 4). This knowledge could ultimately be used to develop new therapeutic vaccines to keep these viruses from taking hold in the body and prevent associated cancers from ever developing in the first place.

Continue reading – Finding new ways to prevent virus-induced stomach cancers

October 4, 2017

New software uses machine learning to identify mutations in tumours without reference tissue samples 

DNA sequence

One of the main steps in analyzing cancer genomic data is to find somatic mutations, which are non-hereditary changes in DNA that may give rise to cancer. To identify these mutations, researchers will often sequence the genome of a patient’s tumour as well as the genome of their normal tissue and compare the results. But what if normal tissue samples aren’t available?

Continue reading – New software uses machine learning to identify mutations in tumours without reference tissue samples 

September 25, 2017

New study uncovers the role of mitochondrial DNA in prostate cancer

An image of mitochondria

Since mitochondria are inherited maternally, it may strike some as an odd place to go looking for connections to prostate cancer. But recently an international research team explored that relationship by looking at how the small amount of DNA contained in mitochondria, a cellular structure, is involved in prostate cancer.

Continue reading – New study uncovers the role of mitochondrial DNA in prostate cancer

September 6, 2017

OICR launches Tissue Portal to support tissue-based research projects

Fu Yan - In the lab.

OICR’s Tissue Portal is a new central entry and exit point for human tissue derived samples handled at OICR. This will serve as a gateway for tissue-based research projects to access over 100 services and resources at OICR being made available through the OICR Collaborative Research Resources on a cost-sharing basis. The Tissue Portal will standardize and streamline the storage, processing and distribution of samples for collaborative research studies at OICR.

Continue reading – OICR launches Tissue Portal to support tissue-based research projects

September 6, 2017

Innovative study brings next-generation genomic sequencing to more Ontario cancer patients

Toronto (September 6, 2017) – Understanding a cancer’s genetics is key to selecting targeted therapies that are likely to be of the most benefit to a patient. The Ontario Institute for Cancer Research (OICR) today announced a new study, called Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE). OCTANE will use next-generation genome sequencing technology to bring a unified molecular profiling approach to five Ontario cancer centres.

Continue reading – Innovative study brings next-generation genomic sequencing to more Ontario cancer patients

August 9, 2017

Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50 per cent of patient tumour samples. The discovery also identifies a new opportunity for targeted therapy.

Continue reading – Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

August 9, 2017

Importance of large database of genetic variants reinforced in a new study

A newly published paper in Genetics in Medicine has reinforced the fundamental importance of collecting information about genetic variances in a single large database.  With so much important genetic information being used globally to understand the underlying genetic influences of diseases, researchers and clinicians need an accessible repository to share this information.

Continue reading – Importance of large database of genetic variants reinforced in a new study

June 7, 2017

EAGLE will help cancer research soar

Dr. Hilary Edgington

 Researchers from OICR and other institutions have created a new software program called EAGLE that mines data to understand the interactions between a person’s environment and their genetics. The tool has far-reaching uses, including oncology, and can provide researchers and clinicians with important information that can help personalize treatments for patients.

To learn more we spoke to Dr. Hillary Edgington, a Postdoctoral Fellow in OICR’s Informatics technology platform, which is led by Dr. Lincoln Stein. Edgington and her collaborators recently shared their research in the journal Nature Methods.

Continue reading – EAGLE will help cancer research soar

June 5, 2017

OICR donates sequencer to Fleming College for high-tech training

Individuals from OICR and Fleming College pose for a photo in front of the sequencer.

Fleming’s Biotechnology-Advanced students have received a significant boost to their career preparation with the help of The Ontario Institute for Cancer Research (OICR). Their investment in people is recognized through a very generous donation of an Illumina HiSeq DNA Sequencer to the Biotechnology-Advanced program, a benefit to Fleming College valued at $600,000. This new equipment will provide students with hands-on experience using cutting-edge automated instruments that are utilized widely across the biotechnology industry.

“Some of the best technicians in OICR’s genomic labs are Fleming College graduates. We are proud to pay-it-forward by helping the College give future life sciences researchers in Ontario hands-on training opportunities on real genomics equipment.” says Paul Krzyzanowski, Program Manager of Genome Technologies, OICR. “Illumina equipment is the backbone of most sequencing labs and it’s essential for today’s students to become familiar with the complexity around these machines with hands-on experience.”

The remarkable relationship between OICR and Fleming College has flourished over the last nine years. With its state of the art facilities and research, OICR has become a highly sought after internship agency for Fleming students since the first placement student in 2008. The support from OICR and Illumina helps Fleming College to lead the way in biotechnology training; contributing to excellence in academic programming that includes relevant experiences. The hands-on learning creates a positive impact towards the future of Fleming students and alumni, the success of employers and especially those who benefit from cancer research.

“We are very grateful for the Ontario Institute of Cancer Research for their investment in our students,” says Biotechnology Program Coordinator Ashvin Mohindra. “OICR provides a practical training component through their in-kind gifts and placement opportunities for our students. With their help, we are also pleased to meet OICRs employment needs which is proven with the hiring of more than 18 Fleming College graduates to fill their high-tech positions.”

The in-kind donation would have not been possible without the tireless effort of OICR and Illumina, the sequencer manufacturer and third party liquid handler software provider. The College would like to specifically recognize and thank everyone at OICR who made these donations possible (Lee Timms, Jessica Miller, Paul Krzyzanowski, Tom Hudson, Mike Kostiuk, Susan Hockley, Jeremy Johns, and Howard Simkevitz) and the staff at Illumina for their tireless help and expertise in setting up the equipment (Lisa Lock, Peter Ayache and Mike Ramsey).

OICR, a global leader in healthcare, research and innovation, is dedicated to exploring the prevention, early detection, diagnosis and treatment of cancer. Their commitment to exploring cancer extends beyond the lab; OICR invests in people who can make novel discoveries.

Note: This story originally appeared in the Spring 2017 edition of Fleming Ties magazine and has been reproduced with the permission of Fleming College. The original can be found here (PDF): https://flemingcollege.ca/PDF/FlemingTies/fleming-ties-spring-2017.pdf

« Previous PageNext Page »